Key growth drivers in Brazil include the expanding population, improved access to healthcare, and the burgeoning middle class which is increasingly opting for branded drugs. Consequently, Big Pharma is targeting Brazil to offset slowing sales growth in more developed markets.
Features and benefits
Report Details:
Published: September 2012
No. of Pages: 139
Price:Single User License:US$5700 Corporate User License:US$14250
Highlights
Overall, health expenditure as a percentage of GDP is increasing which reflects the fact that healthcare and access to treatment (and thus pharmaceutical spending) is an increasing priority for the government.
Intellectual property protection remains problematic for branded pharma, with issues associated with patent linkage, drawn-out patent reviews, conflict between the two agencies involved in assessing patent applications, and the fact that there is no set period of data exclusivity.
Strong market growth in conjunction with improving regulatory standards has led to Brazil becoming a hotbed of investment from both multinational and domestic companies. Big Pharma players are gaining a stronger presence through M&A, benefiting from strong brand image of the local manufacturers.
Your key questions answered
Features and benefits
- Analysis of population demographics, economic wealth, disease burden, level of industrialization, and political structure in Brazil.
- Insight into the healthcare system, drug regulation, drug pricing, drug reimbursement, and intellectual property position in Brazil.
- Assesses the generics and biosimilars landscape in terms of regulatory issues, level of penetration, and key players in Brazil.
- Overview of key market segment sales and top companies, and R&D and manufacturing infrastructure for the leading pharmaceutical companies in Brazil.
Report Details:
Published: September 2012
No. of Pages: 139
Price:Single User License:US$5700 Corporate User License:US$14250
Highlights
Overall, health expenditure as a percentage of GDP is increasing which reflects the fact that healthcare and access to treatment (and thus pharmaceutical spending) is an increasing priority for the government.
Intellectual property protection remains problematic for branded pharma, with issues associated with patent linkage, drawn-out patent reviews, conflict between the two agencies involved in assessing patent applications, and the fact that there is no set period of data exclusivity.
Strong market growth in conjunction with improving regulatory standards has led to Brazil becoming a hotbed of investment from both multinational and domestic companies. Big Pharma players are gaining a stronger presence through M&A, benefiting from strong brand image of the local manufacturers.
Your key questions answered
- How is the regulatory landscape in Brazil changing and what is is the impact of pricing and reimbursement controls on market access in Brazil?
- What are the drivers and resistors of generic and biosimilars uptake in the Brazilian pharmaceutical market?
- Which pharmaceutical market segments in Brazil have the fastest growth rates?
